Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation (NASDAQ: TECH) is a pioneering global life sciences company based in Minnesota. Specializing in bioactive tools and reagents, Bio-Techne serves the research and clinical diagnostic communities. The company's extensive product portfolio, exceeding 275,000 items, supports scientific investigations into biological processes and disease mechanisms, facilitating both drug discovery and accurate clinical testing.
Bio-Techne operates through two main segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment, which accounts for 75% of revenue, provides reagents such as antibodies and analytical instruments for life sciences research. The Diagnostics and Genomics segment, representing 25% of revenue, offers diagnostic reagents and molecular diagnostics, with a strong footprint in spatial biology products.
Geographically, the United States is Bio-Techne's largest market, contributing about 55% of its revenue. The company also maintains significant operations in Europe, the Middle East, Africa (20%), the UK (5%), and Asia-Pacific (15%).
In recent news, Bio-Techne has been active on multiple fronts:
- Legal Actions: Bio-Techne initiated legal proceedings in the Unified Patent Court to address patent infringements related to its RNAscope® ISH technology by Molecular Instruments, Inc.
- Innovations: Partnering with Novomol-Dx, Bio-Techne introduced the Bio-Marker Pathfinder (BMP), a point-of-care ocular biomarker kit leveraging its Ella™ platform for rapid diagnostics in ophthalmic diseases.
- Strategic Collaborations: Bio-Techne entered a distribution agreement with Thermo Fisher Scientific to expand product access across Europe and announced continued collaboration with Regulus Therapeutics, highlighting positive results in ADPKD treatment using Bio-Techne's Simple Western™ platforms.
- Financial Performance: Bio-Techne reported a modest 3% revenue increase for Q3 FY2024 despite challenging market conditions, underscoring strong operational execution and strategic investments.
- Product Showcases: The company unveiled its MauriceFlex™ System at the 72nd ASMS Conference, demonstrating innovative solutions for protein characterization.
With over 3,100 employees worldwide, Bio-Techne generated over $1.1 billion in net sales in fiscal 2023. The company continues to drive significant advancements in life sciences and healthcare through its robust portfolio and strategic initiatives.
Bio-Techne (NASDAQ: TECH) has announced it will host a conference call and webcast on February 5, 2025, at 8:00 a.m. CST to discuss its second quarter fiscal 2025 financial results. Participants can join via phone by dialing 1-877-407-9208 (domestic) or 1-201-493-6784 (international) using Conference ID 13751305. The event will also be accessible through a webcast on the company's investor relations website.
For those unable to attend live, a recorded rebroadcast will be available from 11:00 a.m. CST on February 5 until 11:00 p.m. CST on March 5, 2025. The replay can be accessed by dialing 1-844-512-2921 (domestic) or 1-412-317-6671 (international).
ScaleReady has awarded a $300,000 G-Rex® Grant to BrainChild Bio to support the development of BCB-276, an autologous CAR-T therapy for treating diffuse intrinsic pontine glioma (DIPG), an incurable pediatric brain tumor. The grant is part of ScaleReady's $20M initiative to advance cell and gene-modified cell therapy development.
BrainChild Bio plans to advance BCB-276 into a multi-center Phase 2 pivotal clinical trial in 2025. The grant will help optimize their G-Rex based CAR-T cell manufacturing process, offering process simplicity, consistency, and flexibility. Additionally, BrainChild Bio will have the option to evaluate CellReady's standardized 7-day CAR-T cell process, which uses closed system G-Rex bioreactors and Bio-Techne's ProPak GMP cytokines.
Bio-Techne (NASDAQ: TECH) has announced the launch of new AI-engineered designer proteins through its R&D Systems brand. The expanded portfolio includes IL-2 Heat Stable Agonist, Activin A Hyperactive, FGF basic Heat Stable (available in both RUO and GMP formats), and three Wnt/RSPO Agonist proteins.
These innovative proteins are specifically engineered using advanced AI-based design platforms and protein evolutionary workflows to enhance cellular therapy processes and research applications. The products feature improved functionalities such as hyperactivity, enhanced receptor affinities, and improved heat stability, leveraging generative AI trained on nearly five decades of proteomic leadership.
The new proteins are designed to address critical needs in cell culture performance and optimization, particularly in cellular therapy applications, stem cell research, organoid development, and regenerative medicine.
Bio-Techne (NASDAQ: TECH) announced its participation at Phacilitate's Advanced Therapies Week, scheduled for January 20-23, 2025, in Dallas, Texas. The company will showcase its new ProPak™ GMP cytokines and cell and gene therapy solutions at booth 517.
Key highlights include the integration of ProPak liquid GMP cytokines with Wilson Wolf's G-Rex® bioreactor through ScaleReady, offering a closed process solution for T cell manufacturing. The company will also display the Ella™ automated ELISA platform and Simple Plex™ assays for QC release testing.
Dr. David Hermanson, Principal Scientist, will deliver a breakout session on closed system manufacturing on January 21 and host a product demonstration on January 22, focusing on ProPak cytokines integration in T cell manufacturing workflows. Will Geist, President of Bio-Techne's Protein Sciences Segment, emphasized the company's commitment to efficient manufacturing of cell and gene-modified cell therapies.
ScaleReady has awarded a $125,000 G-Rex Grant to Seattle Children's Therapeutics, a division of Seattle Children's Research Institute. The grant will support the integration of advanced technologies into their CAR-T cell platform, which has already utilized G-Rex bioreactors to manufacture cell therapy products for hundreds of clinical trial participants.
As part of the grant, Seattle Children's Therapeutics will explore fully closed G-Rex bioreactors and Bio-Techne's GMP-grade cytokines to optimize manufacturing for future trials. They will also receive early access to G-Rex product development and participate in evaluating new devices, including cell separation technology that isolates T-cells without expensive instrumentation.
This grant is part of ScaleReady's larger $20M initiative to advance cell and gene-modified cell therapy development and manufacturing, with individual grants worth up to $300,000.
Bio-Techne (NASDAQ: TECH) has won another legal case against Miltenyi Biotec in the Cologne Regional Court, Germany, regarding the unauthorized reverse engineering of Bio-Techne's proprietary NKG2C/CD159c antibodies. The court found that Miltenyi's antibodies had 100% identical variable regions to Bio-Techne's R&D Systems branded products.
This victory follows a similar 2023 case where Miltenyi was found to have reverse engineered Bio-Techne's TIGIT and CCR-7 antibodies. The court has awarded Bio-Techne monetary damages for sales of the reverse engineered antibodies, reimbursement of costs for demonstrating copying, and rights to additional information about Miltenyi's unlawful activities. Miltenyi retains the right to appeal the ruling.
Bio-Techne (NASDAQ: TECH) has announced that its President and CEO, Kim Kelderman, will deliver a presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 14, 2025, at 10:30 a.m. PST. Interested parties can access a live webcast of the presentation through Bio-Techne's Investor Relations website's IR Calendar page.
Bio-Techne (NASDAQ: TECH) has announced a strategic co-marketing and co-promotion agreement with Waters to enhance biotherapeutic characterization and development processes. The partnership combines Bio-Techne's MauriceFlex™ System for charge separation with Waters' BioAccord™ LC-MS System for liquid chromatography mass spectrometry.
The collaboration has already yielded joint activities in late 2024, including an application note, webinar, and presentations at major conferences such as CASSS MS, Festival of Biologics, and PEGS EU. Scientists from both companies are currently working on analyzing additional biomolecule classes, with plans to showcase results at upcoming scientific conferences through various formats including application notes and webinars.
ScaleReady, along with Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH), and CellReady, has awarded a G-Rex® Grant to Moonlight Bio to support their CAR T cell therapy development for solid tumors. The grant is part of ScaleReady's $20M initiative to advance cell and gene-modified cell therapy development.
The grant provides Moonlight Bio with access to a commercial CAR T manufacturing platform, funding for IND-enabling studies validation runs, Bio-Techne's ProPak™ and GMP Cytokines, and optional analysis of manufacturing batch records by CellReady. Individual grants are worth up to $300,000.
Moonlight Bio's technology is based on research published in Nature, focusing on enhancing engineered T cell therapies by utilizing mutations from T cell malignancies.
Bio-Techne (NASDAQ: TECH) has announced a new distribution partnership with MedSanTek to expand its product reach across Turkey and Azerbaijan. The agreement enables MedSanTek to distribute Bio-Techne's portfolio of brands including R&D Systems, Novus, Tocris, Protein Simple, Advanced Cell Diagnostics, and Asuragen.
MedSanTek, founded in the late 2000s, is a leading in vitro diagnostics and research products distributor in the region, specializing in molecular biology, immunology, cancer research, and cell therapy. The partnership aims to leverage MedSanTek's local market expertise and distribution network to enhance Bio-Techne's presence in Turkey and Azerbaijan's biotechnology, laboratory, and hospital sectors.
FAQ
What is the current stock price of Bio-Techne (TECH)?
What is the market cap of Bio-Techne (TECH)?
What does Bio-Techne Corporation do?
What are Bio-Techne's main business segments?
Where is Bio-Techne headquartered?
Which markets does Bio-Techne serve?
What recent legal actions has Bio-Techne taken?
What is the Bio-Marker Pathfinder (BMP) kit?
What was Bio-Techne's financial performance in Q3 FY2024?
What is the MauriceFlex™ System?
How many employees does Bio-Techne have?
What was Bio-Techne's revenue in fiscal 2023?
